Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.89, $0.01 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $397 million versus the consensus estimate of $399.35 million.

GUIDANCE:

Integra LifeSciences sees Q1 2024 EPS of $0.53-$0.57, versus the consensus of $0.75. Integra LifeSciences sees Q1 2024 revenue of $360-365 million, versus the consensus of $380.9 million.

For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, versus the consensus of $1,623 million representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25, versus the consensus of $3.44.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.